Skip to main content

Table 3 MDS categories and risk stratification of the patients included in this study

From: A pilot study on the usefulness of peripheral blood flow cytometry for the diagnosis of lower risk myelodysplastic syndromes: the “MDS thermometer”

Diagnosis (WHO 2016)a

 MDS-RS

6/14 (43%)

 MDS-SLD

4/14 (29%)

 MDS-MLD

3/14 (21%)

 MDS-del(5q)

1/14 (7%)

International Prognostic Scoring System (IPSS)

 IPSS score

0.3 ± 0.4; 0 (0–1.0)

  Score = 0.0

8/14 (57%)

  Score = 0.5

3/14 (21%)

  Score = 1.0

3/14 (21%)

  Score > 1.0

0/14 (0%)

 IPSS risk groups

  Low risk

8/14 (57%)

  Intermediate risk 1

6/14 (43%)

  Intermediate risk 2

0/14 (0%)

  High risk

0/14 (0%)

Cytogenetic based risk classificationb

 Very good

0/10 (0%)

 Good

9/10 (90%)

 Intermediate

1/10 (10%)

 Poor

0/10 (0%)

 Very poor

0/10 (0%)

  1. Abbreviations: IPSS International Prognostic Scoring System, MDS myelodysplastic syndromes, MDS-del(5q) MDS with isolated deletion of chromosome 5q, MDS-MLD MDS with multilineage dysplasia, MDS-RS MDS with ring sideroblasts, MDS-SLD MDS with single lineage dysplasia, WHO World Health Organization
  2. Results are expressed as absolute and (relative) frequencies
  3. a Patients with MDS unclassifiable or with ≥20% blast in the BM were omitted, as did patients with MDS with excess of blasts, and patients diagnosed with Myelodysplastic/myeloproliferative neoplasms
  4. b Cytogenetic scoring: Very good: -Y, del(11q); Good: normal, del(5q), del(12p), del(20q), double including del(5q); Intermediate: del(7q), + 8, + 19, i(17q), any other single or double independent clones; Poor: −7, inv.(3)/t(3q), del3q, double including − 7/del(7q), complex (3 abnormalities); Very poor: complex (> 3 abnormalities)